NCT06344793已完成不适用
A Multi-center Study of the Clinical Outcomes Between Initial CDK 4/6 Inhibitor Plus Endocrine Therapy and Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer in Real World Practice
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 608
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
A multi-center, real world study to evaluate the clinical outcomes between initial CDK 4/6 Inhibitor plus endocrine therapy and initial chemotherapy in HR positive, HER2 negative unresectable or metastatic breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •age >= 18 years old;
- •Patients who were diagnosed as HR Positive, HER2 Negative recurrent unresectable (local or regional) or stage IV (M1) breast cancer between June 2020 to October 2023;
- •Received CDK4/6 inhibitor plus endocrine treatment or chemotherapy as first-line therapy for at least one cycle;
- •Complete medical history was available.
排除标准
- •Medical history was incomplete.
结局指标
主要结局
PFS
时间窗: 6 weeks
progression-free survival
次要结局
- OS(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.Endocrine TherapyBreast CancerCDK4/6 InhibitorsSubsequent TreatmentNCT06033287Hunan Cancer Hospital300
Unknown
1 期
Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System TumorsDigestive System TumorsNCT05139082Peking University60
Unknown
2 期
Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast CancerSolid TumorNCT05512780Hebei Medical University Fourth Hospital30
招募中
2 期
A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCHormone Receptor-positive Breast CancerHormone TherapyBreast CancerNCT05766410National Taiwan University Hospital60
招募中
不适用
Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 InhibitorsAnatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8NCT04526587Roswell Park Cancer Institute700